The stock of AC Immune Ltd (NASDAQ:ACIU) is a huge mover today! The stock decreased 15.84% or $2.17 on November 23, hitting $11.53. About 591,159 shares traded hands or 328.37% up from the average. AC Immune Ltd (NASDAQ:ACIU) has risen 6.00% since October 25, 2016 and is uptrending. It has outperformed by 0.59% the S&P500.
The move comes after 5 months negative chart setup for the $619.94M company. It was reported on Nov, 24 by Barchart.com. We have $11.18 PT which if reached, will make NASDAQ:ACIU worth $18.60 million less.
According to Zacks Investment Research, “AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company’s pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland.”
More recent AC Immune Ltd (NASDAQ:ACIU) news were published by: Globenewswire.com which released: “AC IMMUNE APPOINTS EXPERIENCED LIFE SCIENCE PROFESSIONAL AS NEW CHIEF …” on November 23, 2016. Also Globenewswire.com published the news titled: “AC Immune SA announces results of annual general meeting” on November 15, 2016. Businesswire.com‘s news article titled: “Down Syndrome Pipeline Review, H1 2016 Featuring AC Immune, Aelis Farma S.A.S …” with publication date: March 23, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.